Clinical Trial Update: Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence [Phase 2]

View source ↗

Summary

Phase 2 trial assessing whether oral thalidomide plus tegafur-uracil can decrease recurrence of hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Thalomid (thalidomide)
• UFT (tegafur-uracil)

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED